Acute Myeloid Leukemia
Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Eric Winer, MDAcute Myeloid Leukemia | June 21, 2024
Drs. Winer, Daver, and Abaza discuss the major breakthroughs in the treatment of acute myeloid leukemia.
View More
Eric Winer, MDAcute Myeloid Leukemia | June 17, 2024
Drs. Winer, Abaza, and Daver discuss their own treatment strategies for patients with AML.
Patrick DalyAcute Myeloid Leukemia | June 14, 2024
A reduced venetoclax exposure of seven days was comparable with continual venetoclax exposure in patients with AML.
Andrew MorenoAcute Myeloid Leukemia | June 14, 2024
The first analysis from a phase 1b study shows combination has efficacy even in patients previously on venetoclax.
Andrew MorenoAcute Myeloid Leukemia | June 14, 2024
The updated findings are from a prospective phase II trial presented at the EHA 2024 Hybrid Congress.
Melissa BadamoAcute Myeloid Leukemia | June 3, 2024
Patients who responded to treatment achieved more than 90% bone marrow blast reduction compared with baseline.
Advertisement
Elias Jabbour, MDPrint | May 22, 2024
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Patrick DalyAcute Myeloid Leukemia | May 21, 2024
The patient, a 63-year-old male, was diagnosed with HIV-1 infection 31 years before undergoing transplantation.
Melissa BadamoAcute Myeloid Leukemia | May 21, 2024
Oral tamibarotene is currently being evaluated in combination with azacitidine and venetoclax in the SELECT-AML-1 trial.
Guillermo Garcia-Manero, MDAcute Myeloid Leukemia | May 2, 2024
Early detection and prevention are particularly important in leukemia, Dr. Garcia-Manero explained.
Melissa BadamoPrint | April 30, 2024
Palliative care facilitates communication and helps with symptom management, the researchers noted.
Patrick DalyAcute Myeloid Leukemia | April 26, 2024
FLAG-IDA or DA plus gemtuzumab ozogamicin had differing performance in younger patients with newly diagnosed AML.
Patrick DalyAcute Myeloid Leukemia | April 26, 2024
MRD status after induction chemotherapy predicted benefit from allogeneic transplant in patients with NPM1-mutated AML.
Patrick DalyAcute Myeloid Leukemia | April 26, 2024
Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction.
Michel Zwaan, MD, PhDAcute Lymphoblastic Leukemia | April 22, 2024
A phase II study presented at ASPHO 2024 evaluated revumenib in KMT2A-rearranged ALL and AML.
Melissa BadamoMyelodysplastic Syndromes | April 16, 2024
The average rate of progression for CHIP to MDS or AML is about 1% per year, Dr. Patel explained.
Shaikha Alqahtani, MDAcute Myeloid Leukemia | April 10, 2024
Around 45% of patients had a complete response after cladribine, and 31% proceeded to transplant.
Melissa BadamoAcute Myeloid Leukemia | April 9, 2024
The researchers found that CALM-AF10 leukemia cells grow slower after the SIX1 knockdown.
Leah SherwoodAcute Myeloid Leukemia | April 16, 2024
Claudio Cerchione, MD, PhD, describes his presentation from AACR 2024 on a emavusertib triplet in patients with AML.
Melissa BadamoAcute Myeloid Leukemia | April 10, 2024
The conference has a lot of great sessions, including an untraditional keynote speaker, Dr. Hastings said.
Advertisement
Advertisement
Editorial Board